From professional translators, enterprises, web pages and freely available translation repositories.
deferasirox is an orally active chelator that is highly selective for iron (iii) .
deferasiroksas yra geriamasis chelatus sudarantis preparatas, ypac selektyvus gelezies (iii) jonams.
if you have moderate or severe kidney disease. if you are currently taking any other iron chelator medicines.
jeigu sergate vidutinio sunkumo ar sunkia inkstų liga; jeigu šiuo metu vartojate kokį kitą geležį sujungiantį vaistą.
this is probably due to some extent of complexion of zinc by the chelator, thus reducing the effect of both active substances.
galbūt tai pasireiškia dėl to, kad chelatus sudarantys vaistai šiek tiek jungiasi ir su cinku, taigi mažėja abiejų aktyviųjų medžiagų veiksmingumas.
therefore, it must not be combined with other iron chelator therapies (see section 4.3) .
todl jo negalima vartoti kartu su kitais gelez sujungianciais preparatais (zr.4. 3 skyri) .
however, a post-exposure interval 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.
taciau poekspozicinis intervalas 1val. neuzkerta kelio mazesnio efektyvumo kompleksono naudojimui ir efektyviam veikimui.
it is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload).
tai geležį sujungiantis preparatas, skirtas susikaupusiam per dideliam kiekiui geležies šalinti iš organizmo (tai vadinama geležies pertekliumi).
combination with other iron chelator therapies as the safety of such combinations has not been established (see section 4.5) .
deriniai su kitais gelez sujungianciais preparatais, kadangi nenustatytas toki derini saugumas (zr.4. 5 skyri) .
however, a post-exposure interval > 1 hour does not preclude the administration and effective action of chelator, even if with reduced efficiency.
tačiau net praėjus daugiau kaip valandai, chelatuojančios medžiagos reikia sušvirkšti, nes ji veikia, nors ir ne taip veiksmingai.
as with other iron chelator treatment, high-frequency hearing loss and lenticular opacities (early cataracts) have been uncommonly observed in patients treated with exjade (see section 4.4) .
kaip ir vartojant kitus gelez sujungiancius preparatus, nedaznai exjade vartojantiems pacientams susilpnjo klausa auksto daznio garsams ar pasireisk lsiuko drumstis (ankstyva katarakta) (zr.4. 4 skyri) .